Indaptus Therapeutics, Inc.
INDP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001857044
No open-market purchases or sales by Indaptus Therapeutics, Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $1.15M in total; no superinvestor holds it.
Holders of 5% or more of INDP
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Indaptus Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Lazar David E. | 13D/A | 47.93%2.06M shares | −50.07 ppfrom 98.00% | Mar 2, 20262 filings | Mar 24, 2026 | SEC |
| Yao Yun | 13D/A | 31.51%42.0M shares | −6.29 ppfrom 37.80% | Mar 30, 20262 filings | Jun 26, 2026 | SEC |
| Sino Lion Ventures Ltd | 13D/A | 29.19%38.9M shares | – | Jun 26, 20261 filing | Jun 26, 2026 | SEC |
| Meckler Jeffrey A | 13D/A | 12.70%273.1K shares | – | Dec 30, 20251 filing | Dec 30, 2025 | SEC |
| YA II PN, Ltd. | 13G | 9.99%1.41M shares | New | Feb 18, 20251 filing | Feb 18, 2025 | SEC |
| Dai Junyi | 13D/A | 8.44%11.3M shares | – | Jun 26, 20261 filing | Jun 26, 2026 | SEC |
| Yang Ting | 13D/A | 8.44%11.3M shares | – | Jun 26, 20261 filing | Jun 26, 2026 | SEC |
| Newman Michael James | 13D/A | 5.40%115.6K shares | – | Dec 30, 20251 filing | Dec 30, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
10 Schedule 13D and 13G filings on Indaptus Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Jun 26, 20269:40 PM ET | Sino Lion Ventures Ltdand 1 other | 13D/A | 29.19%38.9M shares | – | Jun 24, 2026 | SEC |
| Jun 26, 20268:00 PM ET | Dai Junyi | 13D/A | 8.44%11.3M shares | – | Jun 24, 2026 | SEC |
| Jun 26, 20268:00 PM ET | Yang Ting | 13D/A | 8.44%11.3M shares | – | Jun 24, 2026 | SEC |
| Jun 26, 20268:00 PM ET | Yao Yun | 13D/A | 31.51%42.0M shares | −6.29 ppfrom 37.80% | Jun 24, 2026 | SEC |
| Mar 30, 20269:46 PM ET | Yao Yunand 5 others | 13D | 37.80%42.0M shares | New | Mar 23, 2026 | SEC |
| Mar 24, 20264:05 PM ET | Lazar David E. | 13D/A | 47.93%2.06M shares | −50.07 ppfrom 98.00% | Mar 23, 2026 | SEC |
| Mar 2, 20265:20 PM ET | Lazar David E. | 13D | 98.00%111.0M shares | New | Feb 26, 2026 | SEC |
| Dec 30, 20254:01 PM ET | Meckler Jeffrey A | 13D/A | 12.70%273.1K shares | – | Dec 22, 2025 | SEC |
| Dec 30, 20254:01 PM ET | Newman Michael James | 13D/A | 5.40%115.6K shares | – | Dec 22, 2025 | SEC |
| Feb 18, 20254:03 PM ET | YA II PN, Ltd.and 7 others | 13G | 9.99%1.41M shares | New | Feb 13, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Indaptus Therapeutics, Inc. shares.
No Form 144 notices for Indaptus Therapeutics, Inc. are on file.